Ramy Riad: Advancing Plasma-Derived Therapies Through Partnership
Ramy Riad, President of Plasma-Derived Therapies Business Unit at Takeda, shared a post on LinkedIn:
“Wrapping up a productive first day at IPPC 2026, hosted by Plasma Protein Therapeutics Association (PPTA), with a real sense of momentum.
This year’s theme — ‘Resilience, Reach and Responsibility’ — perfectly captures the leadership imperative facing our industry.
No single organization can sustain the plasma ecosystem alone.
It requires long‑term partnerships and shared responsibility across the value chain.
Today’s conversations reinforced how essential collaboration is to protect access for the patients who depend on plasma-derived therapies.
Looking forward to the sessions ahead and to connecting with fellow leaders shaping the future of plasma.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials